一种新的纳米粒子疫苗通过培训免疫系统,阻止了小鼠的侵袭性癌症,但需要人类试验。 A new nanoparticle vaccine stopped aggressive cancers in mice by training the immune system, but human trials are needed.

马萨诸塞大学Amherst科学家开发的纳米粒子疫苗,通过训练免疫系统攻击肿瘤细胞,防止小鼠患黑瘤、胰腺癌和三联阴性乳癌等具有攻击性的癌症。 A nanoparticle vaccine developed by University of Massachusetts Amherst scientists prevented aggressive cancers like melanoma, pancreatic, and triple-negative breast cancer in mice by training the immune system to attack tumor cells. 疫苗使用带有癌症特定抗原和强效副药的脂质纳米粒子,在肿瘤接触后达到88%的无癌存活率,停止了转移,并提供了长期免疫。 Using lipid nanoparticles with cancer-specific antigens and a potent adjuvant, the vaccine achieved up to 88% cancer-free survival after tumor exposure, halted metastasis, and provided long-term immunity. 研究人员虽然有希望,但强调人类试验对于确认安全和有效性是必要的。 While promising, researchers stress human trials are needed to confirm safety and effectiveness.